Open AccessHIV virological suppression influences response to the AS 03‐adjuvanted monovalent pandemic influenza A H 1 N 1 vaccine in HIV ‐infected children
Author(s) -
Leahy Timothy R.,
Goode Michelle,
Lynam Paul,
Gavin Patrick J.,
Butler Karina M.
Publication year - 2014
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12243
Subject(s) - medicine , seroconversion , immunogenicity , vaccination , immunology , serology , booster dose , virology , pandemic , population , adverse effect , titer , antibody , disease , covid-19 , infectious disease (medical specialty) , environmental health
Design Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split‐virion AS 03‐adjuvanted pandemic H 1 N 1(2009) vaccine in children with HIV . Setting National referral centre for P aediatric HIV in Ireland. Sample Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition ( HAI ) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40. Main outcome measures The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate ( P = 0·009), magnitude of serological response ( P = 0·02) and presence of seroprotective HAI titres ( P = 0·017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS 03‐adjuvanted pandemic H 1 N 1 vaccine appears to be safe and immunogenic among HIV ‐infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression.